Tradename | Company | Number | Date | Products |
---|---|---|---|---|
OLPRUVA | Acer Therapeutics | N-214860 RX | 2022-12-22 | 6 products, RLD |
BUPHENYL | Horizon Therapeutics Public | N-020573 RX | 1996-04-30 | 1 products, RLD, RS |
BUPHENYL | Horizon Therapeutics Public | N-020572 RX | 1996-05-13 | 1 products, RLD, RS |
PHEBURANE | Medunik | N-216513 RX | 2022-06-17 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RELYVRIO | Amylyx Pharmaceuticals | N-216660 DISCN | 2022-09-29 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
buphenyl | New Drug Application | 2024-10-30 |
olpruva | New Drug Application | 2024-12-18 |
pheburane | New Drug Application | 2024-12-20 |
sodium phenylbutyrate | ANDA | 2024-07-10 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
amyotrophic lateral sclerosis | EFO_0000253 | D000690 | G12.21 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Inborn urea cycle disorders | D056806 | — | E72.2 | 1 | 3 | 3 | 3 | 3 | 13 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | 6 | 1 | 1 | 9 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 6 | 1 | — | 7 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 4 | 3 | — | 1 | 7 |
Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 1 | 4 | 3 | — | 1 | 7 |
Sclerosis | D012598 | — | — | 1 | 4 | 3 | — | 1 | 7 |
Intrahepatic cholestasis | D002780 | — | — | — | 1 | 1 | — | 3 | 4 |
Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 2 | 1 | — | — | 2 |
Inborn genetic diseases | D030342 | EFO_0000508 | — | — | 1 | 1 | — | — | 1 |
Cholestasis | D002779 | — | K83.1 | — | 1 | 1 | — | — | 1 |
Maple syrup urine disease | D008375 | — | E71.0 | — | 1 | 1 | — | — | 1 |
Hemophilia b | D002836 | — | D67 | — | 1 | 1 | — | — | 1 |
Parkinsonian disorders | D020734 | — | G20.C | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 2 | 2 | — | — | — | 4 |
Lymphoma | D008223 | — | C85.9 | 2 | 2 | — | — | — | 4 |
Myelodysplastic syndromes | D009190 | — | D46 | 2 | 1 | — | — | — | 3 |
Syndrome | D013577 | — | — | 1 | 2 | — | — | — | 3 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 3 |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | 3 | 3 | — | — | — | 3 |
Muscular atrophy | D009133 | — | — | 3 | 3 | — | — | — | 3 |
Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | 3 | 3 | — | — | — | 3 |
Atrophy | D001284 | — | — | 3 | 3 | — | — | — | 3 |
Preleukemia | D011289 | — | — | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
Myeloproliferative disorders | D009196 | — | D47.1 | 2 | — | — | — | — | 2 |
Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 2 | — | — | — | — | 2 |
Intestinal neoplasms | D007414 | — | C26.0 | 1 | — | — | — | — | 1 |
Color vision defects | D003117 | — | H53.5 | 1 | — | — | — | — | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Drug common name | Phenylbutanoic acid |
INN | — |
Description | 4-phenylbutyric acid is a monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation. It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an antineoplastic agent, an apoptosis inducer and a prodrug. It is functionally related to a butyric acid. It is a conjugate acid of a 4-phenylbutyrate. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCCc1ccccc1 |
PDB | — |
CAS-ID | 1821-12-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1469 |
ChEBI ID | 41500 |
PubChem CID | — |
DrugBank | — |
UNII ID | — |